Literature DB >> 24162716

Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.

Chuka A Didigu1, Craig B Wilen, Jianbin Wang, Jennifer Duong, Anthony J Secreto, Gwenn A Danet-Desnoyers, James L Riley, Phillip D Gregory, Carl H June, Michael C Holmes, Robert W Doms.   

Abstract

HIV-1 entry into CD4(+) T cells requires binding of the virus to CD4 followed by engagement of either the C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4) coreceptor. Pharmacologic blockade or genetic inactivation of either coreceptor protects cells from infection by viruses that exclusively use the targeted coreceptor. We have used zinc-finger nucleases to drive the simultaneous genetic modification of both ccr5 and cxcr4 in primary human CD4(+) T cells. These gene-modified cells proliferated normally and were resistant to both CCR5- and CXCR4-using HIV-1 in vitro. When introduced into a humanized mouse model of HIV-1 infection, these coreceptor negative cells engraft and traffic normally, and are protected from infection with CCR5- and CXCR4-using HIV-1 strains. These data suggest that simultaneous disruption of the HIV coreceptors may provide a useful approach for the long-term, drug-free treatment of established HIV-1 infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24162716      PMCID: PMC3879906          DOI: 10.1182/blood-2013-08-521229

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

Review 1.  Hematopoietic-stem-cell-based gene therapy for HIV disease.

Authors:  Hans-Peter Kiem; Keith R Jerome; Steven G Deeks; Joseph M McCune
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

Review 2.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

Review 3.  Novel cell and gene therapies for HIV.

Authors:  James A Hoxie; Carl H June
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 4.  Combined approaches for HIV cure.

Authors:  David M Margolis; Daria J Hazuda
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

Review 5.  Creating genetic resistance to HIV.

Authors:  John C Burnett; John A Zaia; John J Rossi
Journal:  Curr Opin Immunol       Date:  2012-09-15       Impact factor: 7.486

6.  Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.

Authors:  Timothy J Henrich; Zixin Hu; Jonathan Z Li; Gaia Sciaranghella; Michael P Busch; Sheila M Keating; Sebastien Gallien; Nina H Lin; Francoise F Giguel; Laura Lavoie; Vincent T Ho; Philippe Armand; Robert J Soiffer; Manish Sagar; Ann S Lacasce; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2013-03-04       Impact factor: 5.226

7.  FLASH assembly of TALENs for high-throughput genome editing.

Authors:  Deepak Reyon; Shengdar Q Tsai; Cyd Khayter; Jennifer A Foden; Jeffry D Sander; J Keith Joung
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

8.  Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.

Authors:  Craig B Wilen; Jianbin Wang; John C Tilton; Jeffrey C Miller; Kenneth A Kim; Edward J Rebar; Scott A Sherrill-Mix; Sean C Patro; Anthony J Secreto; Andrea P O Jordan; Gary Lee; Joshua Kahn; Pyone P Aye; Bruce A Bunnell; Andrew A Lackner; James A Hoxie; Gwenn A Danet-Desnoyers; Frederic D Bushman; James L Riley; Philip D Gregory; Carl H June; Michael C Holmes; Robert W Doms
Journal:  PLoS Pathog       Date:  2011-04-14       Impact factor: 6.823

9.  Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Authors:  Nicholas F Parrish; Craig B Wilen; Lauren B Banks; Shilpa S Iyer; Jennifer M Pfaff; Jesus F Salazar-Gonzalez; Maria G Salazar; Julie M Decker; Erica H Parrish; Anna Berg; Jennifer Hopper; Bhavna Hora; Amit Kumar; Tatenda Mahlokozera; Sally Yuan; Charl Coleman; Marion Vermeulen; Haitao Ding; Christina Ochsenbauer; John C Tilton; Sallie R Permar; John C Kappes; Michael R Betts; Michael P Busch; Feng Gao; David Montefiori; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  PLoS Pathog       Date:  2012-05-31       Impact factor: 6.823

10.  Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.

Authors:  Lijing Li; Ludmila Krymskaya; Jianbin Wang; Jill Henley; Anitha Rao; Lan-Feng Cao; Chy-Anh Tran; Monica Torres-Coronado; Agnes Gardner; Nancy Gonzalez; Kenneth Kim; Pei-Qi Liu; Ursula Hofer; Evan Lopez; Philip D Gregory; Qing Liu; Michael C Holmes; Paula M Cannon; John A Zaia; David L DiGiusto
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

View more
  64 in total

1.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Taylor Mesojednik; Guillermo S Romano Ibarra; Jaya Sahni; Alison Bernard; Karen Sommer; Andrew M Scharenberg; David J Rawlings; Thor A Wagner
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

2.  Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing.

Authors:  Xiangjin Kang; Wenyin He; Yuling Huang; Qian Yu; Yaoyong Chen; Xingcheng Gao; Xiaofang Sun; Yong Fan
Journal:  J Assist Reprod Genet       Date:  2016-04-06       Impact factor: 3.412

Review 3.  Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication.

Authors:  David L DiGiusto
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Gene transfer of two entry inhibitors protects CD4⁺ T cell from HIV-1 infection in humanized mice.

Authors:  N Y Petit; C Baillou; A Burlion; K Dorgham; B Levacher; C Amiel; V Schneider; F M Lemoine; G Gorochov; G Marodon
Journal:  Gene Ther       Date:  2015-10-21       Impact factor: 5.250

Review 5.  The clinical applications of genome editing in HIV.

Authors:  Cathy X Wang; Paula M Cannon
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

6.  Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor.

Authors:  Lihong Liu; Michael Wen; Qianqian Zhu; Jason T Kimata; Paul Zhou
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-07       Impact factor: 4.147

Review 7.  Gene editing and its application for hematological diseases.

Authors:  Mark J Osborn; Joseph J Belanto; Jakub Tolar; Daniel F Voytas
Journal:  Int J Hematol       Date:  2016-05-27       Impact factor: 2.490

Review 8.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

9.  High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.

Authors:  Kamila S Gwiazda; Alexandra E Grier; Jaya Sahni; Stephen M Burleigh; Unja Martin; Julia G Yang; Nicholas A Popp; Michelle C Krutein; Iram F Khan; Kyle Jacoby; Michael C Jensen; David J Rawlings; Andrew M Scharenberg
Journal:  Mol Ther       Date:  2016-05-16       Impact factor: 11.454

10.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.

Authors:  Kathrin Schumann; Steven Lin; Eric Boyer; Dimitre R Simeonov; Meena Subramaniam; Rachel E Gate; Genevieve E Haliburton; Chun J Ye; Jeffrey A Bluestone; Jennifer A Doudna; Alexander Marson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.